1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Panacos Pharmaceuticals, Inc.

Panacos Pharmaceuticals, Inc.

PANC
Panacos Pharmaceuticals, Inc.US flagOther OTC
0.00
USD
- -
- -
5,367.00Market Cap
1997 Y
1998 Y
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
TTM
Revenue per Share
21.94
32.33
28.29
20.5
12.05
1.86
2.67
1.39
0.03
0.01
- -
- -
Basic EPS, GAAP
-16.2
-6.12
-27.85
-7.54
-10.49
-8.81
-13
-14.51
-1.72
-0.75
-0.7
-0.67
Free Cash Flow per Basic Share
-18.83
-11.38
-6.29
-9.82
-6.55
-9.84
-9.82
-10.24
-0.63
-0.6
-0.58
-0.58
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
-36.97
-31.66
-52.37
-42.88
-48.65
-56.52
-374.01
-26.33
-2.44
-2.42
-3
-3.47
Tangible Book Value per Share
16.2
51.27
38.14
20.78
13.11
4.17
22.65
-27.9
2.49
1.16
0.54
0.1
Basic Weighted Avg Shares
1
1
1
2
2
2
- -
1
34
51
53
54
Sales/Revenue/Turnover
16
34
38
41
27
4
1
1
1
- -
- -
- -
Operating Margin (%)
-67.84
-13.61
-8.32
-37.45
-62.3
-483.8
-401.76
-895.21
-3,867.21
-14,681.34
-21,678.89
-34,568.69
Depreciation Expense
3
3
3
4
3
1
- -
- -
1
1
1
1
Net Income, GAAP
-12
-6
-37
-15
-23
-20
-5
-12
-59
-38
-37
-36
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-73.85
-18.93
-98.43
-36.8
-87.09
-474.33
-418.18
-900.37
-5,631.84
-13,419.01
-20,810.56
-36,116.16
Working Capital
-3
33
21
4
23
5
6
2
83
56
43
15
LT Debt
13
11
5
1
- -
- -
- -
- -
- -
- -
17
11
Total Equity
12
54
55
45
33
13
12
-26
86
59
29
5
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
ST Debt
5
6
7
LT Borrowings
15
13
11
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
54
54
54
Market Capitalization
4
2
2

Working Capital

FRC

•

in mil. unless spec.
Mar'08
Jun'08
Sep'08
Total Current Assets
45
37
28
Cash, Cash Equivalents & STI
44
36
27
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
10
13
13
Payables & Accruals
6
7
6
ST Debt
5
6
7
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-57.19%
-165.34%
-50.8%
Free Cash Flow
34.69%
45.83%
3.1%
Net Income, GAAP
86.31%
88.62%
-1.71%
Sales/Revenue/Turnover
-16.69%
-36.31%
-36.62%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
-0.13
-0.3
-0.16
- -
-0.75
2007
-0.19
-0.19
-0.15
- -
-0.7
2008
-0.16
-0.18
-0.15
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2006
- -
- -
- -
- -
- -
2007
- -
- -
- -
- -
- -
2008
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
John R. Barr
Full Time Employees
41
Sector
Healthcare
Industry
Biotechnology
Address
134 Coolidge Avenue Watertown United States of America 02472
IPO Date
Mar 14, 2005
Website
panacos.com
Similar Companies
PureTech Health plc (PRTC.L)
Miromatrix Medical Inc. (MIRO)
Abpro Corporation (ABP)
Shanghai Haohai Biological Technology Co., Ltd. (688366.SS)
Advicenne S.A. (ADVIC.PA)
Repare Therapeutics Inc. (RPTX)
Business
Panacos Pharmaceuticals, Inc. was a biotechnology enterprise dedicated to identifying and advancing small-molecule oral therapies for human immunodeficiency virus (HIV) and other viral infections. The firm’s research efforts targeted critical stages within the viral life cycle, specifically focusing on mechanisms such as virus maturation and fusion. Its pipeline included innovative programs aimed at inhibiting HIV maturation, with a lead candidate, bevirimat (PA-457), demonstrating activity against drug-resistant HIV strains. Initially established in 1999 and based in Watertown, Massachusetts, the company later underwent a reverse merger with V.I. Technologies in 2005, which then assumed the Panacos name and ticker PANC. Despite promising clinical trial results for its primary compound, Panacos Pharmaceuticals ultimately delisted from Nasdaq and ceased independent operations in early 2009, with its HIV drug development programs subsequently acquired by Myriad Pharmaceuticals.